Transurethral prostate surgery as a preventive method against progression of chronic kidney disease in patients with urodynamically proven bladder outlet obstruction
The present study was aimed to investigate (1) whether urodynamic factors are responsible for kidney damage in patients with bladder outlet obstruction (BOO) and (2) whether transurethral prostate surgery for BOO can alleviate the damage to the kidneys.
This prospective observational study involved men aged 50–80 years. Prostate size and urodynamic test were performed during screening period. Laboratory tests to measure the glomerular filtration rate, the urinary protein to creatinine ratio and dipstick urinalysis were performed before and 6 months after the transurethral prostate surgery.
Sixty-seven patients completed the laboratory study among a hundred enrolled patients with urodynamically proven BOO. Among the urodynamic parameters, only low bladder compliance (lower than 60 mL/cmH2O) was associated with clinically significant proteinuria (p < 0.001). Transurethral prostate surgery significantly improved proteinuria (p = 0.007), especially in patients with low bladder compliance (p = 0.004), and subsequently decreased the risk grade of CKD progression (p < 0.001).
Low bladder compliance in patients with BOO may be a risk factor for kidney damage. Transurethral prostate surgery to relieve BOO could be a preventive method against CKD progression in patients with low bladder compliance.
KeywordsBenign prostate hyperplasia Urinary bladder Compliance Proteinuria Chronic kidney disease
The authors wish to acknowledge the financial support from the Catholic Medical Center Research Foundation in the program year of 2016. We are particularly grateful to Inae Park (Department of Urology, St. Vincent’s Hospital) for assisting with data processing.
DSL: protocol development, manuscript writing, data collection, data analysis; HWK: manuscript editing, data analysis; SJL: protocol development, manuscript editing.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The institutional review board approved the observational study design and access to the patients’ medical records (approval number: VC13OISI0222, date of approval: February 26th, 2014). Additionally, this project was registered at ClinicalTrials.gov (Register no: L201401N1). This study was performed in accordance with the Declaration of Helsinki. This article does not contain any studies with animals performed by any of the authors.
Informed consent was obtained from all individual participants in the study.
- 1.National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–266Google Scholar
- 12.James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA 311(5):507–520PubMedCrossRefPubMedCentralGoogle Scholar
- 16.Smith HW (1951) Measurement of the filtration rate. The kidney: structure and function in health and disease. Oxford University Press, New York, pp 39–62Google Scholar
- 20.Summary of recommendation statements (2013) Kidney Int Suppl (2011) 3(3):5–14Google Scholar
- 23.Yamamoto H, Yamamoto K, Yoshida K, Shindoh C, Takeda K, Monden M et al (2015) Modified cut-off value of the urine protein-to-creatinine ratio is helpful for identifying patients at high risk for chronic kidney disease: validation of the revised Japanese guideline. Tohoku J Exp Med 237(3):201–207PubMedCrossRefPubMedCentralGoogle Scholar
- 38.McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398PubMedCrossRefPubMedCentralGoogle Scholar
- 39.Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F, CombAT Study Group (2009) The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol 55(2):461–471PubMedCrossRefPubMedCentralGoogle Scholar
- 47.Cho MC, Ha SB, Park J et al (2016) Impact of detrusor underactivity on surgical outcomes of laser prostatectomy: comparison in serial 12-month follow-up outcomes between potassium-titanyl-phosphate photoselective vaporization of the prostate (PVP) and holmium laser enucleation of the prostate (HoLEP). Urology 91:158–166PubMedCrossRefPubMedCentralGoogle Scholar